Piper Sandler raised the firm’s price target on Fulcrum Therapeutics (FULC) to $23 from $16 and keeps an Overweight rating on the shares. The firm notes Fulcrum reported positive PIONEER data at ASH. The company plans to report full 12-week Phase Ib PIONEER data in Q1 2026 and meet with the FDA to discuss a registrational trial for pociredir in sickle cell disease to start in the second half of 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC:
- Fulcrum Therapeutics price target raised to $25 from $18 at H.C. Wainwright
- Fulcrum announces results from 20 mg dose cohort of Phase 1b PIONEER trial
- Fulcrum Therapeutics initiated with a Buy at Truist
- Buy Rating for Fulcrum Therapeutics Driven by Promising PIONEER Study Results and Market Potential of Pociredir
- Fulcrum Therapeutics: Promising Sickle Cell Treatment with Pociredir Outshines Competitors